scholarly journals SP172RISK FACTORS ASSOCIATED WITH VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH IGA NEPHROPATHY AND NEPHROTIC SYNDROME: A PROSPECTIVE OBSERVATIONAL STUDY

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii435-iii435
Author(s):  
Gener Ismail ◽  
Andreea Andronesi ◽  
Raluca Bobeica ◽  
Roxana Jurubita ◽  
Simona Ioanitescu
Keyword(s):  
Nephrotic Syndrome ◽  
Observational Study ◽  
Iga Nephropathy ◽  
Prospective Observational Study ◽  
Thromboembolic Events ◽  
Factors Associated ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

scholarly journals Venous thromboembolic events in patients with COVID-19: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Ting Wu ◽  
Zhihong Zuo ◽  
Deyi Yang ◽  
Xuan Luo ◽  
Liping Jiang ◽  
...  
Keyword(s):  
Fixed Effects ◽  
Meta Analysis ◽  
Adverse Outcomes ◽  
Thromboembolic Events ◽  
Severe Condition ◽  
Factors Associated ◽  
Reactive Protein ◽  
Online Databases ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

Abstract Background High incidence of venous thromboembolic complications in coronavirus disease 2019 (COVID-19) patients was noted recently. Objective This study aimed to explore the factors associated with prevalence of venous thromboembolism (VTE) in COVID-19 patients. Methods A literature search was conducted in several online databases. Fixed effects meta-analysis was performed for the factors associated with prevalence of VTE in COVID-19 patients. Results A total of 39 studies were analysed in this analysis. The incidence of pulmonary embolism and VTE in severe COVID-19 patients were 17% (95% CI, 13–21%) and 42% (95% CI, 25–60%), respectively. VTE were more common among individuals with COVID-19 of advance age. Male COVID-19 patients are more likely to experience VTE. Higher levels of white blood cell (WBC; WMD = 1.34 × 109/L; 95% CI, 0.84–1.84 × 109/L), D-dimer (WMD = 4.21 μg/ml; 95% CI, 3.77–4.66 μg/ml), activated partial thromboplastin time (APTT; WMD = 2.03 s; 95% CI, 0.83–3.24 s), fibrinogen (WMD = 0.49 μg/ml; 95% CI, 0.18–0.79 g/L) and C-reactive protein (CRP; WMD = 21.89 mg/L; 95% CI, 11.44–32.34 mg/L) were commonly noted in COVID-19 patients with VTE. Patients with lower level of lymphocyte (WMD = −0.15 × 109/L; 95% CI, −0.23-−0.07 × 109/L) was at high risk of developing VTE. The incidence of severe condition (OR = 2.66; 95% CI, 1.95–3.62) was more likely to occur among COVID-19 patients who developed VTE. Conclusion VTE is a common complication in severe COVID-19 patients and thromboembolic events are also associated with adverse outcomes.

Risk Factors Associated with Venous Thromboembolic Events in Patients with Malignancy.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2592-2592
Author(s):  
Jules Lin ◽  
Hang Li ◽  
Thomas W. Wakefield ◽  
Peter K. Henke
Keyword(s):  
Solid Tumors ◽  
Advanced Age ◽  
Thromboembolic Events ◽  
University Of Michigan ◽  
Vte Prophylaxis ◽  
Factors Associated ◽  
Increased Risk ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
The University

Abstract Malignancy is a major risk factor for venous thromboembolic events (VTE), but not all patients with malignancy develop this complication. Who best to aggressively prophylax is thus not well defined. In the current study, 960 consecutive patients, 523 men and 437 women, admitted to the University of Michigan with malignancy between 1992–2000 were identified using ICD-9CM codes. Factors including cancer stage, type, therapy, and patient vital status were obtained from a database maintained prospectively by the University of Michigan Cancer Registry as well as a review of the medical record. Acute VTE, confirmed on radiological or ultrasound studies, occurred in 408 patients and were compared to 552 patients who did not experience any VTE using logistic regression analysis. Factors associated with VTE include solid tumors (Odds Ratio 5.0; 95% confidence interval 1.65–14.9, P =.004), infection (4.9; 1.2–19.8, P =.025), and advanced age (1.05; 1.03–1.08, P <.001). Interestingly, while leukopenia (4.2; 1.23–14.6, P =.023) was associated with an increased incidence of VTE, neutropenia was not, suggesting that a deficiency of a different class of leukocytes is more important in predisposing to primary VTE. Neutropenia was associated with recurrent, but not primary VTE (P =.034). Type of therapy, gender, and stage were not associated with VTE. Kaplan Meier estimated survival was decreased in patients with VTE as compared to those without (3.3 vs. 3.7 years, P=.18). Factors associated with a decreased survival include solid tumors (3.9; 1.8–8.4, P <.01), infection (3.3; 1.1–9.9, P =.03), advanced stage (1.6; 1.2–2.1, P <.01), and increased age (1.02; 1.0–1.04, P =.01). Patients with solid tumors, advanced age, and leukopenia have a significantly increased risk of VTE and might benefit from aggressive VTE prophylaxis, whereas other patients with malignancy can probably be carefully observed.

scholarly journals Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants

2020 ◽  
Author(s):  
Niklas Wallvik ◽  
Henrik Renlund ◽  
Anders Själander
Keyword(s):  
Risk Factors ◽  
Major Bleeding ◽  
Oral Anticoagulants ◽  
New Oral Anticoagulants ◽  
Thromboembolic Events ◽  
Cox Regression Analysis ◽  
Factors Associated ◽  
Previous Stroke ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

Abstract New oral anticoagulants (NOACs) is the preferred treatment in secondary prophylaxis of venous thromboembolic events (VTE). The aim of this study was to investigate possible risk factors associated with major bleeding in VTE-patients treated with NOACs. In this retrospective register-based study we screened the Swedish anticoagulation register Auricula (during 2012.01.01–2017.12.31) to find patients and used other national registers for outcomes. Primary endpoint was major bleeding defined as bleeding leading to hospital care. Multivariate Cox-regression analysis was used to reveal risk factors. 18 219 patients with NOAC due to VTE were included. 85.6% had their first VTE, mean age was 69.4 years and median follow-up time was 183 days. The most common NOAC was rivaroxaban (54.8%), followed by apixaban (42.0%), dabigatran (3.2%) and edoxaban (0.1%). The rate of major bleeding was 6.62 (95% CI 6.19–7.06) per 100 treatment years in all patients and 11.27 (CI 9.96–12.57) in patients above 80 years of age. Statistically independent risk factors associated with major bleeding were age (normalized HR 1.38, CI 1.27–1.50), earlier major bleeding (HR 1.58, Cl 1.09–2.30), COPD (HR 1.28, CI 1.04–1.60) and previous stroke (HR 1.28, Cl 1.03–1.58) or transient ischemic attack (TIA) (HR 1.33, Cl 1.01–1.76). Prior warfarin treatment was protective (HR 0.67, CI 0.58–0.78). This real world cohort shows a high bleeding rate especially among the elderly and in patients with previous major bleeding, COPD and previous stroke or TIA. This should be considered when deciding on treatment duration and NOAC dose in these patients.

scholarly journals Risk Factors for Postoperative Venous Thromboembolic Events in Patients Undergoing Lumbar Spine Surgery

2018 ◽  
Vol 9 (4) ◽  
pp. 409-416 ◽  
Author(s):  
Alexander Nazareth ◽  
Anthony D’Oro ◽  
John C. Liu ◽  
Kyle Schoell ◽  
Patrick Heindel ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lumbar Spine ◽  
Spine Surgery ◽  
Lumbar Spine Surgery ◽  
Thromboembolic Events ◽  
Lumbar Surgery ◽  
Factors Associated ◽  
Patient Demographics ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

Study Design: Retrospective, database study. Objectives: The aim of this study was to investigate incidence and risk factors associated with venous thromboembolic events (VTEs) after lumbar spine surgery. Methods: Patients who underwent lumbar surgery between 2007 and 2014 were identified using the Humana within PearlDiver database. ICD-9 (International Classification of Diseases Ninth Revision) diagnosis codes were used to search for the incidence of VTEs among surgery types, patient demographics and comorbidities. Complications including DVT and PE were queried each day from the day of surgery to postoperative day 7 and for periods 0 to 1 week, 0 to 1 month, 0 to 2 months, and 0 to 3 months postoperatively. Results: A total of 64 892 patients within the Humana insurance database received lumbar surgery between 2007 and 2014. Overall VTE rate was 0.9% at 1 week, 1.8% at 1 month, and 2.6% at 3 months postoperatively. Among patients that developed a VTE within 1 week postoperatively, 45.3% had a VTE on the day of surgery. Patients with 1 or more identified risk factors had a VTE incidence of 2.73%, compared with 0.95% for patients without risk factors ( P < .001). Risk factors associated with the highest VTE incidence and odds ratios (ORs) were primary coagulation disorder (10.01%, OR 4.33), extremity paralysis (7.49%, OR 2.96), central venous line (6.70%, OR 2.87), and varicose veins (6.51%, OR 2.58). Conclusions: This study identified several patient comorbidities that were independent predictors of postoperative VTE occurrence after lumbar surgery. Clinical VTE risk assessment may improve with increased focus toward patient comorbidities rather than surgery type or patient demographics.

scholarly journals Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome

2017 ◽  
Vol 32 (1) ◽  
pp. 157-164 ◽  
Author(s):  
Geeta Gyamlani ◽  
Miklos Z. Molnar ◽  
Jun L. Lu ◽  
Keiichi Sumida ◽  
Kamyar Kalantar-Zadeh ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Serum Albumin ◽  
Serum Albumin Level ◽  
Albumin Level ◽  
Large Cohort ◽  
Thromboembolic Events ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

scholarly journals What are the barriers to the completion of a home-based rehabilitation programme for patients awaiting surgery for lung cancer: a prospective observational study

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e041907
Author(s):  
Heloise Catho ◽  
Sebastien Guigard ◽  
Anne-Claire Toffart ◽  
Gil Frey ◽  
Thibaut Chollier ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Living Alone ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Factors Associated ◽  
Home Based ◽  
Registration Number

ObjectivesHome-based rehabilitation programmes (H-RPs) could facilitate the implementation of pulmonary rehabilitation prior to resection for non-small cell lung cancer (NSCLC), but their feasibility has not been evaluated. The aim of this study was to identify determinants of non-completion of an H-RP and the factors associated with medical events occurring 30 days after hospital discharge.DesignA prospective observational study.InterventionAll patients with confirmed or suspected NSCLC were enrolled in a four-component H-RP prior to surgery: (i) smoking cessation, (ii) nutritional support, (iii) physiotherapy (at least one session/week) and (iv) home cycle-ergometry (at least three times/week).OutcomesThe H-RP was defined as ‘completed’ if the four components were performed before surgery.ResultsOut of 50 patients included, 42 underwent surgery (80% men; median age: 69 (IQR 25%–75%; 60–74) years; 64% Chronic Obstructive Pulmonary Disease (COPD); 29% type 2 diabetes). Twenty patients (48%) completed 100% of the programme. The median (IQR) duration of the H-RP was 32 (19; 46) days. Multivariate analysis showed polypharmacy (n=24) OR=12.2 (95% CI 2.0 to 74.2), living alone (n=8) (single vs couple) OR=21.5 (95% CI 1.4 to >100) and a long delay before starting the H-RP (n=18) OR=6.24 (95% CI 1.1 to 36.6) were independently associated with a risk of non-completion. In univariate analyses, factors associated with medical events at 30 days were H-RP non-completion, diabetes, polypharmacy, social precariousness and female sex.ConclusionFacing multiple comorbidities, living alone and a long delay before starting the rehabilitation increase the risk of not completing preoperative H-RP.Trial registration numberNCT03530059.

scholarly journals Recurrence of Upper Extremity Deep Vein Thrombosis Secondary to COVID-19

Viruses ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 878
Author(s):  
Yesha H. Parekh ◽  
Nicole J. Altomare ◽  
Erin P. McDonnell ◽  
Martin J. Blaser ◽  
Payal D. Parikh
Keyword(s):  
Deep Vein Thrombosis ◽  
Lower Extremity ◽  
Upper Extremity ◽  
Thromboembolic Events ◽  
Vein Thrombosis ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
Deep Vein

Infection with SARS-CoV-2 leading to COVID-19 induces hyperinflammatory and hypercoagulable states, resulting in arterial and venous thromboembolic events. Deep vein thrombosis (DVT) has been well reported in COVID-19 patients. While most DVTs occur in a lower extremity, involvement of the upper extremity is uncommon. In this report, we describe the first reported patient with an upper extremity DVT recurrence secondary to COVID-19 infection.

Sign in / Sign up

Export Citation Format

Share Document